Novo Nordisk hikes 2026 outlook again as Wegovy pill beats forecasts
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
This report does not map to a usual set of affected companies.
Directly affected
- NVO Novo Nordisk A S-0.3% 30d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Novo Nordisk A/S belongs to, so it often moves with news about it.
- NVS Novartis AG-3.2% 8d
Novartis AG is a peer of Novo Nordisk A/S in pharmaceutical preparations; rivals often move on the same news.
- AZN AstraZeneca+13.4% 30d
AstraZeneca is a peer of Novo Nordisk A/S in pharmaceutical preparations; rivals often move on the same news.
- GSK Gsk+0.7% 5d
Gsk is a peer of Novo Nordisk A/S in pharmaceutical preparations; rivals often move on the same news.
- SNY Sanofi
Sanofi is a peer of Novo Nordisk A/S in pharmaceutical preparations; rivals often move on the same news.
- ROIV Roivant Sciences+14.5% 18d
Roivant Sciences is a peer of Novo Nordisk A/S in pharmaceutical preparations; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| NVO | -4.80% | -0.53% | base | +4.87% | -0.36% | +0.22% | +2.93% |
| XLV | -2.31% | +0.48% | base | +3.08% | +0.65% | +0.47% | +2.39% |
| NVS | -1.99% | +0.99% | base | +3.62% | +1.58% | +2.12% | +2.77% |
| AZN | -7.81% | +1.49% | base | +2.78% | +1.79% | +1.38% | +2.98% |
| GSK | +0.04% | +1.60% | base | +4.94% | +3.34% | +3.24% | +5.76% |
| SNY | -6.81% | -2.11% | base | +4.67% | +3.11% | +3.72% | +6.16% |
| ROIV | +2.87% | +2.36% | base | +5.99% | +1.58% | +7.92% | +12.77% |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Novo Nordisk hikes 2026 outlook again as Wegovy pill beats forecasts Reuters
Source: Reuters
This story
| Company | When | Move | Status |
|---|---|---|---|
| AZN | that day | +2.78% | final price |
| AZN | the next day | +1.79% | final price |
| AZN | two days later | +1.38% | final price |
| AZN | three days later | +2.98% | final price |
| AZN | three days earlier | +1.49% | final price |
| AZN | five days earlier | -7.81% | final price |
| GSK | that day | +4.94% | final price |
| GSK | the next day | +3.34% | final price |
| GSK | two days later | +3.24% | final price |
| GSK | three days later | +5.76% | final price |
| GSK | three days earlier | +1.60% | final price |
| GSK | five days earlier | +0.04% | final price |
| NVO | that day | +4.87% | final price |
| NVO | the next day | -0.36% | final price |
| NVO | two days later | +0.22% | final price |
| NVO | three days later | +2.93% | final price |
| NVO | three days earlier | -0.53% | final price |
| NVO | five days earlier | -4.80% | final price |
| NVS | that day | +3.62% | final price |
| NVS | the next day | +1.58% | final price |
| NVS | two days later | +2.12% | final price |
| NVS | three days later | +2.77% | final price |
| NVS | three days earlier | +0.99% | final price |
| NVS | five days earlier | -1.99% | final price |
| ROIV | that day | +5.99% | final price |
| ROIV | the next day | +1.58% | final price |
| ROIV | two days later | +7.92% | final price |
| ROIV | three days later | +12.77% | final price |
| ROIV | three days earlier | +2.36% | final price |
| ROIV | five days earlier | +2.87% | final price |
| SNY | that day | +4.67% | final price |
| SNY | the next day | +3.11% | final price |
| SNY | two days later | +3.72% | final price |
| SNY | three days later | +6.16% | final price |
| SNY | three days earlier | -2.11% | final price |
| SNY | five days earlier | -6.81% | final price |
| XLV | that day | +3.08% | final price |
| XLV | the next day | +0.65% | final price |
| XLV | two days later | +0.47% | final price |
| XLV | three days later | +2.39% | final price |
| XLV | three days earlier | +0.48% | final price |
| XLV | five days earlier | -2.31% | final price |
Congressional trades in the stocks in this story
- Rep. Kevin Hern sold Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 10 Sep 2026. That is 55 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Kevin Hern sold Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 31 Aug 2026. That is 65 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Scott Scott Franklin bought Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 26 Aug 2026. That is 70 days before publication. Filed 17 Sep 2026. View the filing.
- Rep. Kevin Hern sold Novartis Ag (NVS), worth $15,001 - $50,000 on 27 Aug 2026. That is 69 days before publication. Filed 25 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
This story
12 out of 100
“Novo Nordisk hikes 2026 outlook again as Wegovy pill beats forecasts” scores 12 out of 100. The score uses 1 sources.